VTRS Viatris Inc.
Company Analysis
Latest News
🟢 Viatris is trading 6% up in after-hours trading
Viatris is trading 6.34% up at $17.12 after-hours on August 12, 2026, following a $16.10 regular-session close; searches found no clear company-specific...
🟢 Viatris is trading 4.59% up in pre-market after Q2 earnings beat and raised 2026 guidance
Viatris is trading 4.59% up at $17.04 after its August 6, 2026 second-quarter earnings beat. - Revenue reached $3.8 billion, while adjusted EPS was $0.69,...
🔴 Viatris is trading 4.2% down today as China and supply risks overshadowed earnings beat
Viatris is trading 4.2% down at $16.91 after investors appeared to weigh second-half risks tied to China, supply disruptions, and competition despite...
Viatris's second quarter revenue of $3.8B beat estimates as the company raised its full-year 2026 guidance.
Viatris reported second quarter total revenues of $3.8 billion, a 5% increase year-over-year, and an adjusted EPS of $0.69, up 11%. The company posted a U.S....
Viatris Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Viatris Inc. is expected to report Q2 2026 revenue of $3.66 billion and EPS of $0.62 on August 06, 2026, with the current stock price of $17.63 trading...
Viatris Wins FDA Approval for Gwyn Lo Weekly Contraceptive Patch
Viatris received U.S. Food and Drug Administration (FDA) approval for Gwyn Lo, a once-weekly transdermal contraceptive patch. The low-dose estrogen product...
🟢 Viatris is trading 4.1% up today on healthcare sector strength and pipeline optimism
Viatris is trading at $17.36 (+4.1%), extending its multi-day uptrend despite a weaker broader market. • The move is largely driven by a rally in healthcare...
Viatris Enters ¥40 Billion Amended and Restated Term Loan Credit Agreement
Viatris Inc. has entered into an amended and restated term loan credit agreement, establishing a ¥40 billion senior unsecured term loan facility. The proceeds...
Viatris reports 33% protein reduction in Phase 3 Japan kidney trial
Viatris announced positive top-line results from a Phase 3 trial of VR-205 in Japanese adults. The drug treats primary immunoglobulin A nephropathy (IgAN), a...
🔴 VTRS is trading 5.1% down today after insider stock sale near 52-week highs
VTRS is trading 5.1% down at $15.50 following an after-hours pullback triggered by headlines regarding an insider stock sale near 52-week highs. • Interim CFO...
Viatris Completes €650 Million Offering of 4.250% Senior Notes Due 2033
Viatris Inc. has completed a public offering of €650 million in senior unsecured notes to refinance existing debt. The proceeds are intended to fund the...
🔴 Viatris Inc. is trading 4.5% down today, extending a multi-day pullback on profit-taking
Viatris Inc. is trading 4.5% down at $15.02, extending a multi-day pullback from recent closes above $16. • The decline appears to be a continuation of recent...
Viatris Announces €650 Million Offering of 4.250% Senior Notes Due 2033
Viatris Inc. has entered into an underwriting agreement to issue and sell €650 million in senior notes. The offering is expected to close on June 17, 2026,...